0

Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Type and Geography - Forecast and Analysis 2021-2025

  • Published: Jan 2022
  • Pages: 120
  • SKU: IRTNTR71927
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

The Duchenne muscular dystrophy (DMD) therapeutics market share is expected to increase by USD 1.17 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 18.92%.

This Duchenne muscular dystrophy therapeutics market research will help companies evaluate their business approaches. Furthermore, this report extensively covers Duchenne muscular dystrophy therapeutics market segmentation by type (biologics and small molecules) and geography (North America, Europe, Asia, and ROW). The Duchenne muscular dystrophy therapeutics market report also offers information on several market vendors, including AFM-Telethon, Capricor Therapeutics Inc., CRISPR Therapeutics AG, Daiichi Sankyo Co. Ltd., Editas Medicine Inc., F. Hoffmann-La Roche Ltd., Italfarmaco Spa, Nippon Shinyaku Co. Ltd., Pfizer Inc., and PTC Therapeutics Inc. among others.

What will the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size be During the Forecast Period?

Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size

Download the Free Report Sample to Unlock the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size for the Forecast Period and Other Important Statistics

 

Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Key Drivers, Trends, and Challenges

The high unmet need is notably driving the Duchenne muscular dystrophy (DMD) therapeutics market growth, although factors such as high treatment costs may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the Duchenne muscular dystrophy (DMD) therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Duchenne Muscular Dystrophy (DMD) Therapeutics Market Driver

One of the key factors driving the global Duchenne muscular dystrophy (DMD) therapeutics market growth is the high unmet need for the treatment of muscular dystrophies. DMD is the second most prevalent hereditary childhood myopathy, leading to progressive muscle weakening and atrophy and premature death. Animal models with natural mutations or those caused by gene targeting have significantly contributed to the development of effective therapeutics for DMD. This, in turn, has led to the identification of various therapeutic targets, such as dystrophin-based therapies like EXONDYS 51 and TRANSLARNA. Currently, corticosteroid (EMFLAZA) and the off-label use of various heart medications represent the gold standard for the treatment of DMD. The high unmet need for affordable therapies creates a significant opportunity for new vendors to enter the market, which is expected to support the market growth in the coming years.

Key Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trend

Another key factor driving the global Duchenne muscular dystrophy (DMD) therapeutics market growth is the strong pipeline. Vendors are developing novel therapeutics such as antisense oligonucleotide-based therapy, gene therapy, cell therapy, biologics, and small molecule-based drugs to cater to market demand. The pipeline for DMD also has three therapeutic candidates being evaluated in Phase III of clinical trials and two in Phase II/III of clinical trials. For instance, in January 2021, Pfizer Inc. announced that the first participant had been dosed in the Phase 3 CIFFREO study, which would evaluate the efficacy and safety of investigational gene therapy candidate PF-06939926 in boys with DMD. Such initiatives are estimated to bring opportunities for the market in the forecast period.

Key Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenge

One of the key challenges to the global Duchenne muscular dystrophy (DMD) therapeutics market growth is the high treatment costs. DMD is a rare and fatal genetic disorder that primarily affects the male population and causes muscle weakness in early childhood. Despite the high efficacy of DMD therapeutics, the high cost of therapies imposes an economic burden on patients and their families. For instance, the annual cost associated with the treatment of DMD using EXONDYS 51 is estimated to be approximately USD 300,000. Similarly, the annual cost of treatment associated with EMFLAZA is estimated to be USD 35,000 for male patients who weigh up to 25 kg, and the treatment cost rises with an increase in weight. Thus, the expensive cost of treatment is expected to challenge the global DMD therapeutics market growth during the forecast period.

This Duchenne muscular dystrophy (DMD) therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Parent Market Analysis

Technavio categorizes the global Duchenne muscular dystrophy (DMD) therapeutics market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the Duchenne muscular dystrophy (DMD) therapeutics market during the forecast period.

Who are the Major Duchenne Muscular Dystrophy (DMD) Therapeutics Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

  • AFM-Telethon
  • Capricor Therapeutics Inc.
  • CRISPR Therapeutics AG
  • Daiichi Sankyo Co. Ltd.
  • Editas Medicine Inc.
  • F. Hoffmann-La Roche Ltd.
  • Italfarmaco Spa
  • Nippon Shinyaku Co. Ltd.
  • Pfizer Inc.
  • PTC Therapeutics Inc.

This statistical study of the Duchenne muscular dystrophy (DMD) therapeutics market encompasses successful business strategies deployed by the key vendors. The Duchenne muscular dystrophy (DMD) therapeutics market is fragmented and the vendors are deploying growth strategies such as technological innovations to compete in the market.

Product Insights and News

  • AFM-Telethon - The company offers Duchenne Muscular Dystrophy (DMD) therapeutics namely GNT 0004.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The Duchenne muscular dystrophy (DMD) therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Duchenne Muscular Dystrophy (DMD) Therapeutics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the Duchenne muscular dystrophy (DMD) therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chains is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Duchenne Muscular Dystrophy (DMD) Therapeutics Market?

Duchenne Muscular Dystrophy (DMD) Therapeutics Market Market segmentation by region

For more insights on the market share of various regions Request for a FREE sample now!

40% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for Duchenne muscular dystrophy (DMD) therapeutics in North America. Market growth in this region will be slower than the growth of the market in Europe and Asia.

The increase in adoption of highly effective and approved therapeutics such as EXONDYS 51 by Sarepta and EMFLAZA and TRANSLARNA by PTC Therapeutics will facilitate the Duchenne muscular dystrophy (DMD) therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The COVID-19 outbreak led to a slight decline in the growth of the DMD therapeutics market in North America in Q1 2020, owing to the temporary pause on the research of new drugs for DMD treatment and reduced clinic visits because of the stay-at-home policy. However, factors such as the adoption of telehealth and the lifting of stay-at-home policies regained the market revenue in the region, which is expected to drive the growth of the regional market during the forecast period.

What are the Revenue-generating Type Segments in the Duchenne Muscular Dystrophy (DMD) Therapeutics Market?

Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segmentation

To gain further insights on the market contribution of various segments Request for a FREE sample

The Duchenne muscular dystrophy (DMD) therapeutics market share growth by the biologics segment will be significant during the forecast period. The presence of multiple biologics in the late stages of clinical trials, such as RO7239361, a myostatin inhibitor by Roche, will drive the market growth through this segment in focus in the coming years. 

This report provides an accurate prediction of the contribution of all the segments to the growth of the Duchenne muscular dystrophy (DMD) therapeutics market size and actionable market insights on post COVID-19 impact on each segment.

Duchenne Muscular Dystrophy (DMD) Therapeutics Market Scope

Report Coverage

Details

Page number

120

Base year

2020

Forecast period

2021-2025

Growth momentum & CAGR

Accelerate at a CAGR of 18.92%

Market growth 2021-2025

$ 1.17 billion

Market structure

Fragmented

YoY growth (%)

17.76

Regional analysis

North America, Europe, Asia, and ROW

Performing market contribution

North America at 40%

Key consumer countries

US, Canada, Germany, China, and UK

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

AFM-Telethon, Capricor Therapeutics Inc., CRISPR Therapeutics AG, Daiichi Sankyo Co. Ltd., Editas Medicine Inc., F. Hoffmann-La Roche Ltd., Italfarmaco Spa, Nippon Shinyaku Co. Ltd., Pfizer Inc., and PTC Therapeutics Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report?

  • CAGR of the market during the forecast period 2021-2025
  • Detailed information on factors that will drive Duchenne muscular dystrophy (DMD) therapeutics market growth during the next five years
  • Precise estimation of the Duchenne muscular dystrophy (DMD) therapeutics market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the Duchenne muscular dystrophy (DMD) therapeutics market across North America, Europe, Asia, and ROW
  • A thorough analysis of the market's competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of Duchenne muscular dystrophy (DMD) therapeutics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Executive Summary

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type

  • Market segments
  • Comparison by Type
  • Biologics - Market size and forecast 2020-2025
  • Small molecules - Market size and forecast 2020-2025
  • Market opportunity by Type

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor Landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AFM-Telethon
  • Capricor Therapeutics Inc.
  • CRISPR Therapeutics AG
  • Daiichi Sankyo Co. Ltd.
  • Editas Medicine Inc.
  • F. Hoffmann-La Roche Ltd.
  • Italfarmaco Spa
  • Nippon Shinyaku Co. Ltd.
  • Pfizer Inc.
  • PTC Therapeutics Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

TechnavioINFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases
Technavio

TechnavioDATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts
Technavio

TechnavioREPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your sample now!
Duchenne Muscular Dystrophy (DMD) Therapeutics market growth will increase by $1175.08 million during 2020-2025.
The duchenne muscular dystrophy (dmd) therapeutics market is expected to grow at a CAGR of 18.92% during 2020-2025.
Technavio has segmented the duchenne muscular dystrophy (dmd) therapeutics market by type (Biologics and Small molecules) and geographic (North America, Europe, Asia, and ROW).
AFM-Telethon, Capricor Therapeutics Inc., CRISPR Therapeutics AG, Daiichi Sankyo Co. Ltd., Editas Medicine Inc., F. Hoffmann-La Roche Ltd., Italfarmaco Spa, Nippon Shinyaku Co. Ltd., Pfizer Inc., PTC Therapeutics Inc. are a few of the key vendors in the duchenne muscular dystrophy (dmd) therapeutics market.
North America will register the highest growth rate of 39.52% among the other regions. Therefore, the duchenne muscular dystrophy (dmd) therapeutics market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
The key factors driving the duchenne muscular dystrophy (dmd) therapeutics market growth are:
  • High unmet need
The duchenne muscular dystrophy (dmd) therapeutics market vendors should focus on grabbing business opportunities from the biologics segment as it accounted for the largest market share in the base year.
  • What are the key global market and the regional market share?
  • What are the revenue-generating key market segments?
  • What are the key factors driving and challenging this market’s growth?
  • Who are the key market vendors and their growth strategies?
  • What are the latest trends influencing the growth of this market?
  • What are the variables influencing the market growth in the primary regions?
  • What are the factors influencing the growth of the parent market?
  • Off-the-shelf research reports
  • Reports can be tailored to meet the customer's needs
  • Trusted by more than 100 fortune 500 organizations
  • Information about the market's key drivers, trends, and challenges
  • Parent market analysis
  • Every week, 50,000 people visit our subscription platform
  • Detailed vendors report with competitive landscape
  • Covid-19 impact and recovery analysis
  • Data on revenue-generating market segments
  • Details on the market shares of various regions
  • Five-force market analysis

Certified ISO 9001 : 2015

We are ISO recognized

We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

We are GDPR and CCPA compliant

We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

Safe and Secure SSL Encrypted
Technavio

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Customized Report as per your Business Needs

  • Our analysts will work directly with you and understand your needs
  • Get data on specified regions or segments, competitor and Vendors
  • Data will be formatted and presented as per your requirements
  • We offer $1000 worth of FREE customization at the time of purchase

Let us help you make report more suited to your requirements.

  • Get a competitive breakdown as per your niche industry
  • Customize the data with various metrics that meet your business prerequisite
  • Understand Revenue Sources, Customers and many more
  • Details on Market Share
  • These customizations are done in a short amount of time by our analysts and industry experts
Technavio
Enquire Before Buying
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>